These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 30873381)

  • 21. Radiogenomics of diffuse intrinsic pontine gliomas (DIPGs): correlation of histological and biological characteristics with multimodal MRI features.
    Calmon R; Dangouloff-Ros V; Varlet P; Deroulers C; Philippe C; Debily MA; Castel D; Beccaria K; Blauwblomme T; Grevent D; Levy R; Roux CJ; Purcell Y; Saitovitch A; Zilbovicius M; Dufour C; Puget S; Grill J; Boddaert N
    Eur Radiol; 2021 Dec; 31(12):8913-8924. PubMed ID: 34003354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histone Variant and Cell Context Determine H3K27M Reprogramming of the Enhancer Landscape and Oncogenic State.
    Nagaraja S; Quezada MA; Gillespie SM; Arzt M; Lennon JJ; Woo PJ; Hovestadt V; Kambhampati M; Filbin MG; Suva ML; Nazarian J; Monje M
    Mol Cell; 2019 Dec; 76(6):965-980.e12. PubMed ID: 31588023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pediatric Diffuse Midline Glioma H3K27-Altered: From Developmental Origins to Therapeutic Challenges.
    Mandorino M; Maitra A; Armenise D; Baldelli OM; Miciaccia M; Ferorelli S; Perrone MG; Scilimati A
    Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncohistone Mutations in Diffuse Intrinsic Pontine Glioma.
    Zhang X; Zhang Z
    Trends Cancer; 2019 Dec; 5(12):799-808. PubMed ID: 31813457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis.
    Borsuk R; Zhou L; Chang WI; Zhang Y; Sharma A; Prabhu VV; Tapinos N; Lulla RR; El-Deiry WS
    Am J Cancer Res; 2021; 11(9):4607-4623. PubMed ID: 34659909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigenetic programming of pediatric high-grade glioma: Pushing beyond proof of concept to clinical benefit.
    Groves A; Cooney TM
    Front Cell Dev Biol; 2022; 10():1089898. PubMed ID: 36589742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Signal Transduction in Diffuse Intrinsic Pontine Glioma.
    Duchatel RJ; Jackson ER; Alvaro F; Nixon B; Hondermarck H; Dun MD
    Proteomics; 2019 Nov; 19(21-22):e1800479. PubMed ID: 31328874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential Expression of Wilms' Tumor Protein in Diffuse Intrinsic Pontine Glioma.
    Lee S; Kambhampati M; Yadavilli S; Gordish-Dressman H; Santi M; Cruz CR; Packer RJ; Almira-Suarez MI; Hwang EI; Nazarian J
    J Neuropathol Exp Neurol; 2019 May; 78(5):380-388. PubMed ID: 30990879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201.
    Xin DE; Liao Y; Rao R; Ogurek S; Sengupta S; Xin M; Bayat AE; Seibel WL; Graham RT; Koschmann C; Lu QR
    Neuro Oncol; 2024 Apr; 26(4):735-748. PubMed ID: 38011799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo.
    Silveira AB; Kasper LH; Fan Y; Jin H; Wu G; Shaw TI; Zhu X; Larson JD; Easton J; Shao Y; Yergeau DA; Rosencrance C; Boggs K; Rusch MC; Ding L; Zhang J; Finkelstein D; Noyes RM; Russell BL; Xu B; Broniscer A; Wetmore C; Pounds SB; Ellison DW; Zhang J; Baker SJ
    Acta Neuropathol; 2019 Apr; 137(4):637-655. PubMed ID: 30770999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diffuse midline glioma-H3K27M mutant. A novel entity with a defining and specific IHC marker.
    Agarwal P; Aiyer HM
    Indian J Pathol Microbiol; 2021; 64(2):351-353. PubMed ID: 33851633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The H3K27M mutation alters stem cell growth, epigenetic regulation, and differentiation potential.
    Kfoury-Beaumont N; Prakasam R; Pondugula S; Lagas JS; Matkovich S; Gontarz P; Yang L; Yano H; Kim AH; Rubin JB; Kroll KL
    BMC Biol; 2022 May; 20(1):124. PubMed ID: 35637482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
    Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
    J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diffuse intrinsic pontine gliomas-current management and new biologic insights. Is there a glimmer of hope?
    Cohen KJ; Jabado N; Grill J
    Neuro Oncol; 2017 Aug; 19(8):1025-1034. PubMed ID: 28371920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paediatric Gliomas: BRAF and Histone H3 as Biomarkers, Therapy and Perspective of Liquid Biopsies.
    Tan JY; Wijesinghe IVS; Alfarizal Kamarudin MN; Parhar I
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33557011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New
    Plessier A; Le Dret L; Varlet P; Beccaria K; Lacombe J; Mériaux S; Geffroy F; Fiette L; Flamant P; Chrétien F; Blauwblomme T; Puget S; Grill J; Debily MA; Castel D
    Oncotarget; 2017 Aug; 8(32):52543-52559. PubMed ID: 28881750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma.
    Bailey CP; Figueroa M; Gangadharan A; Yang Y; Romero MM; Kennis BA; Yadavilli S; Henry V; Collier T; Monje M; Lee DA; Wang L; Nazarian J; Gopalakrishnan V; Zaky W; Becher OJ; Chandra J
    Neuro Oncol; 2020 Sep; 22(9):1302-1314. PubMed ID: 32166329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma.
    Tsoli M; Shen H; Mayoh C; Franshaw L; Ehteda A; Upton D; Carvalho D; Vinci M; Meel MH; van Vuurden D; Plessier A; Castel D; Drissi R; Farrell M; Cryan J; Crimmins D; Caird J; Pears J; Francis S; Ludlow LEA; Carai A; Mastronuzzi A; Liu B; Hansford J; Gottardo N; Hassall T; Kirby M; Fouladi M; Hawkins C; Monje M; Grill J; Jones C; Hulleman E; Ziegler DS
    J Neurooncol; 2019 Jan; 141(2):253-263. PubMed ID: 30446898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment Strategies in Diffuse Midline Gliomas With the H3K27M Mutation: The Role of Convection-Enhanced Delivery in Overcoming Anatomic Challenges.
    Himes BT; Zhang L; Daniels DJ
    Front Oncol; 2019; 9():31. PubMed ID: 30800634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histone tail analysis reveals H3K36me2 and H4K16ac as epigenetic signatures of diffuse intrinsic pontine glioma.
    An S; Camarillo JM; Huang TY; Li D; Morris JA; Zoltek MA; Qi J; Behbahani M; Kambhampati M; Kelleher NL; Nazarian J; Thomas PM; Saratsis AM
    J Exp Clin Cancer Res; 2020 Nov; 39(1):261. PubMed ID: 33239043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.